Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer.


OBJECTIVE The CCP signature test (Prolaris) quantifies a patient's risk of disease progression and prostate cancer specific mortality using a gene-expression-based cell cycle progression (CCP) score. This study evaluated the potential clinical utility of the CCP test in a US-based clinical setting. METHODS Urologists who participated in a prospective… (More)
DOI: 10.1185/03007995.2013.873398